Selected Grants
A randomized, part A partial blinded and part B double blinded, placebo-controlled 24-week clinical study to evaluate the efficacy and safety of nomacopan therapy in adult patients with bullous pemphigoid receiving adjunct oral corticosteroid therapy
Clinical TrialPrincipal Investigator · Awarded by Akari Therapeutics · 2022 - 2023A Phase I, Open-Label, Multicenter Trial Exploring the Safety and Tolerability of Autologous Polyclonal Regulatory T Cell Therapy in Adults with Active Pemphigus
Clinical TrialPrincipal Investigator · Awarded by Emory University · 2019 - 2021An Open-Label, Proof of Concept Study Designed to Evaluate the Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients with Newly Diagnosed, Moderate to Extensive Bullous Pemphigoid
Clinical TrialPrincipal Investigator · Awarded by Immune Pharmaceuticals · 2016 - 2020A Phase 1b, Multicenter, Open-Label, Safety, Tolerability, and Activity Study of SYNT001 in Subjects with Chronic Pemphigus (Vulgaris or Foliaceus)
Clinical TrialPrincipal Investigator · Awarded by Syntimmune, Inc. · 2017 - 2020A Phase I, Open-Label, Multicenter Trial Exploring the Safety and Tolerability of Autologous Polyclonal Regulatory T Cell Therapy in Adults with Active Pemphigus
Clinical TrialPrincipal Investigator · Awarded by University of California - San Francisco · 2017 - 2019A randomized, part A partial blinded and part B double blinded, placebo-controlled 24-week clinical study to evaluate the efficacy and safety of nomacopan therapy in adult patients with bullous pemphigoid receiving adjunct oral corticosteroid therapy
Clinical TrialPrincipal Investigator · Awarded by Akari Therapeutics · 2022 - 2023A Phase I, Open-Label, Multicenter Trial Exploring the Safety and Tolerability of Autologous Polyclonal Regulatory T Cell Therapy in Adults with Active Pemphigus
Clinical TrialPrincipal Investigator · Awarded by Emory University · 2019 - 2021An Open-Label, Proof of Concept Study Designed to Evaluate the Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients with Newly Diagnosed, Moderate to Extensive Bullous Pemphigoid
Clinical TrialPrincipal Investigator · Awarded by Immune Pharmaceuticals · 2016 - 2020A Phase 1b, Multicenter, Open-Label, Safety, Tolerability, and Activity Study of SYNT001 in Subjects with Chronic Pemphigus (Vulgaris or Foliaceus)
Clinical TrialPrincipal Investigator · Awarded by Syntimmune, Inc. · 2017 - 2020A Phase I, Open-Label, Multicenter Trial Exploring the Safety and Tolerability of Autologous Polyclonal Regulatory T Cell Therapy in Adults with Active Pemphigus
Clinical TrialPrincipal Investigator · Awarded by University of California - San Francisco · 2017 - 2019Training Program in Inflammatory and Immunological Diseases
Inst. Training Prgm or CMEPreceptor · Awarded by National Institutes of Health · 1980 - 2017Depression & CHD: Cellular-Molecular Mechanisms
Clinical TrialCo Investigator · Awarded by National Institutes of Health · 2009 - 2017Duke Skin Diseases Research Core Center
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2014 - 2016CYLD Regulation of Epidermal Growth and Neoplasia
ResearchMentor · Awarded by National Institutes of Health · 2007 - 2010NF-kB, CDK4 and JNK in Epidermal Growth Regulation
ResearchCo-Mentor · Awarded by National Institutes of Health · 2005 - 2010Dermatitis herpetiformis and the mucosal immune response
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2000 - 2006Dermatology Training Grant
Inst. Training Prgm or CMEPrincipal Investigator · Awarded by National Institutes of Health · 1975 - 1998Dermatology Training Program
Inst. Training Prgm or CMEPrincipal Investigator · Awarded by National Institutes of Health · 1993 - 1996Dermatitis Herpetiformis And The Mucosal Immune Response
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1992 - 1993Dermatitis Herpetiformis And The Mucossal Immune Response
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1989 - 1993Dermatitis Herpetiformis & The Mucosal Immune Response
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1985 - 1988Dermatitis Herpetiformis And The Mucosal Immune Response
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1986 - 1988External Relationships
- Argenx
- Charlotte AHEC
- Cowen and Company
- Guidepost
- International Societies for Investigative Dermatology
- Argenx
- Charlotte AHEC
- Cowen and Company
- Guidepost
- International Societies for Investigative Dermatology
- Logan Logan and Reed LC, Kansas city Missouri
- Priovan Therapeutics
- Quinn Emanuel Urquhart and Sullivan LLP
- Sanofi
- Society for Investigative Dermatology
- cabaletta Bio, Inc
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.